Apax Partners’ Sale Of Neuraxpharm To Permira Funds


Linklaters has advised funds managed by Apax Partners on the deal.

Apax Partners sold shares in Neuraxpharm, a leading European pharmaceutical company focusing on the treatment of central nervous system disorders, to funds advised by Permira. This is reported to be the biggest European pharma deal of 2020.

Neuraxpharm is active in 13 countries and covers around 80 percent of the European drug market for the treatment of central nervous system disorders. The company generates annual sales of more than 460 million euros and employs over 850 people.

The Linklaters team advising on the deal was led by private equity Partners Ben Rodham (Picture – London) and Ralph Drebes (Frankfurt) supported by private equity Managing Associates Ben Suen (London) and Nikita Selivanov (Frankfurt).

Involved fees earner: Ralph Drebes – Linklaters; Ben Rodham – Linklaters; Nikita Selivanov – Linklaters; Ben Suen – Linklaters;

Law Firms: Linklaters;

Clients: Apax Partners;